SCHEMBL5652008

SCHEMBL5652008

CN(C(=O)Oc1ccc(NC(=O)C2CCCCC2)cc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.65
KMT2A Q03164 2/20 0.65
HPGD P15428 1/20 0.58
ENPP3 O14638 7/20 0.56
ENPP1 P22413 7/20 0.56
ENPP2 Q13822 4/20 0.56
RAB9A P51151 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
PTPN1 P18031 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
STS P08842 1/20 0.51
LIPE Q05469 1/20 0.49
ALDH1A1 P00352 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5647177 0.87 GLA (0.65) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL5651210 0.87 GLA (0.65) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL5647180 0.87 GLA (0.65) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL5646367 0.83 ALDH1A1 (0.49) MEN1KMT2AHPGDRAB9ASMN1; SMN2
SCHEMBL5650567 0.83 KMT2A (0.61) MEN1KMT2ARAB9ASMN1; SMN2NPC1
SCHEMBL26154085 0.78 HPGD (0.73) HPGDENPP3ENPP1ENPP2RAB9A
SCHEMBL5650526 0.76 RAB9A (0.59) MEN1KMT2AHPGDRAB9ASMN1; SMN2
SCHEMBL19703413 0.76 HPGD (1.00) MEN1KMT2AHPGDENPP3ENPP1
SCHEMBL1300190 0.76 HPGD (1.00) MEN1KMT2AHPGDENPP3ENPP1
SCHEMBL5651882 0.75 MEN1 (0.71) MEN1KMT2ARAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148799-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US claimed
EP-1636201-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111025-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP claimed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US claimed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO claimed
US-7279470-B2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2007-10-09 US disclosed
US-20060148799-A1 Substituted p-phenyl carbamates NOVO NORDISK A/S (DK) 2006-07-06 US disclosed
US-7067517-B2 Use of compounds for decreasing activity of hormone-sensitive lipase NERO NORDISK A/S (DK) 2006-06-27 US disclosed
EP-1636201-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111025-A1 PARA-SUBSTITUTED PHENYL CARBAMATES AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive NOVO NORDISK A/S (DK) 2003-09-04 US disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148799-A1 Substituted p-phenyl carbamates LIPE, PNLIP, LPL MEN1 2927/4885KMT2A 2057/4885HPGD 1916/4885
US-20030166644-A1 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase LIPE, PNLIP, LPL MEN1 2277/4885KMT2A 4150/4885HPGD 444/4885
US-20030166690-A1 Use of compounds for decreasing activity of hormone-sensitive LIPE, PNLIP, LPL MEN1 1767/4885KMT2A 4322/4885HPGD 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.